{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T21:43:07Z","timestamp":1778967787616,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuroradiology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study presents a retrospective analysis of palliative intra-arterial chemoperfusion (IAC) for patients with symptomatic breast cancer brain metastases (BCBM) aiming to investigate the safety and efficacy of the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirteen patients with BCBM were treated using a total of 64 IACs, averaging 4.9 per patient. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan\u2013Meier method. Response to IAC was evaluated according to RECIST 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were no treatment-related major complications. A total of three patients (3\/11) developed progressive disease. Five (5\/11) patients achieved stable disease, two (2\/11) partial response, and one (1\/11) complete response, resulting in a local tumor control rate of 73% (8\/11). Two (2\/13) patients could not be evaluated according to RECIST 1.1. The median OS time was 8.2 months (95% CI: 7.7\u20138.7), and the median PFS time was 7.9 months (95% CI: 0.0\u201316.3). The mean OS time was 14.5 months (95% CI: 3.4\u201325.6), and the mean PFS time was 10.6 months (95% CI: 2.6\u201318.6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IAC can be applied as a safe method for palliative patients with BCBM. Further studies are necessary to definitively determine its efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00234-026-03988-9","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:04:13Z","timestamp":1775804653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intra-arterial chemoperfusion for breast cancer brain metastases: safety and efficacy"],"prefix":"10.1007","author":[{"given":"Hamzah","family":"Adwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon V.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"12","key":"3988_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J et al (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121(12):991\u20131000. https:\/\/doi.org\/10.1038\/s41416-019-0619-y","journal-title":"Br J Cancer"},{"issue":"1","key":"3988_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","volume":"124","author":"C Bailleux","year":"2021","unstructured":"Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124(1):142\u2013155. https:\/\/doi.org\/10.1038\/s41416-020-01175-y","journal-title":"Br J Cancer"},{"issue":"10","key":"3988_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s11864-022-01011-w","volume":"23","author":"A Dhakal","year":"2022","unstructured":"Dhakal A, Van Swearingen AED, O\u2019Regan R, Anders CK (2022) Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. Curr Treat Options Oncol 23(10):1457\u20131476. https:\/\/doi.org\/10.1007\/s11864-022-01011-w","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"3988_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11060-020-03435-6","volume":"147","author":"RS D\u2019Amico","year":"2020","unstructured":"D\u2019Amico RS, Khatri D, Reichman N et al (2020) Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going. J Neurooncol 147(2):261\u2013278. https:\/\/doi.org\/10.1007\/s11060-020-03435-6","journal-title":"J Neurooncol"},{"issue":"6","key":"3988_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11864-005-0030-1","volume":"6","author":"HB Newton","year":"2005","unstructured":"Newton HB (2005) Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol 6(6):519\u2013530. https:\/\/doi.org\/10.1007\/s11864-005-0030-1","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"3988_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1023\/A:1006104220315","volume":"41","author":"N Takeda","year":"1999","unstructured":"Takeda N, Diksic M (1999) Relationship Between Drug Delivery and the Intra-arterial Infusion Rate of SarCNU in C6 Rat Brain Tumor Model. J Neurooncol 41(3):235\u2013246. https:\/\/doi.org\/10.1023\/A:1006104220315","journal-title":"J Neurooncol"},{"issue":"3","key":"3988_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/159101991101700302","volume":"17","author":"JK Burkhardt","year":"2011","unstructured":"Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA (2011) Intra-Arterial Chemotherapy for Malignant Gliomas: A Critical Analysis. Interv Neuroradiol 17(3):286\u2013295. https:\/\/doi.org\/10.1177\/159101991101700302","journal-title":"Interv Neuroradiol"},{"issue":"4","key":"3988_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cncr.22450","volume":"109","author":"D Fortin","year":"2007","unstructured":"Fortin D, Gendron C, Boudrias M, Garant M (2007) Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 109(4):751\u2013760. https:\/\/doi.org\/10.1002\/cncr.22450","journal-title":"Cancer"},{"issue":"4","key":"3988_CR9","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.neurad.2025.101351","volume":"52","author":"TJ Vogl","year":"2025","unstructured":"Vogl TJ, Stein LV, R\u00f6del C, Bielfeldt J, Adwan H (2025) Efficacy and safety of intra-arterial chemoperfusion as palliative treatment of symptomatic primary brain malignancies. J Neuroradiol 52(4):101351. https:\/\/doi.org\/10.1016\/j.neurad.2025.101351","journal-title":"J Neuroradiol"},{"issue":"2","key":"3988_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"9 Pt 2","key":"3988_CR11","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1097\/01.rvi.0000094584.83406.3e","volume":"14","author":"D Sacks","year":"2003","unstructured":"Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol JVIR 14(9 Pt 2):S199\u2013202. https:\/\/doi.org\/10.1097\/01.rvi.0000094584.83406.3e","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"1","key":"3988_CR12","doi-asserted-by":"publisher","first-page":"vdac104","DOI":"10.1093\/noajnl\/vdac104","volume":"4","author":"K Uluc","year":"2022","unstructured":"Uluc K, Ambady P, McIntyre MK et al (2022) Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors. Neuro-Oncol Adv 4(1):vdac104. https:\/\/doi.org\/10.1093\/noajnl\/vdac104","journal-title":"Neuro-Oncol Adv"},{"issue":"2","key":"3988_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2018.08.018","volume":"129","author":"H Aiyama","year":"2018","unstructured":"Aiyama H, Yamamoto M, Kawabe T et al (2018) Complications after stereotactic radiosurgery for brain metastases: Incidences, correlating factors, treatments and outcomes. Radiother Oncol 129(2):364\u2013369. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.018","journal-title":"Radiother Oncol"}],"container-title":["Neuroradiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00234-026-03988-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00234-026-03988-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00234-026-03988-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:04:14Z","timestamp":1775804654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00234-026-03988-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":13,"alternative-id":["3988"],"URL":"https:\/\/doi.org\/10.1007\/s00234-026-03988-9","relation":{},"ISSN":["0028-3940","1432-1920"],"issn-type":[{"value":"0028-3940","type":"print"},{"value":"1432-1920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study approval was granted by the local Ethics Committee of the Goethe University Hospital Frankfurt. Informed consent of a patient to participate in this study was waived due to its retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}